This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Bone marrow transplant (BMT)	Thymus cell antigen 1 τ (THY1; CD90); endoglin (ENG; CD105)	A study in mice suggests that specific bone-derived progenitor cells could help improve hematopoietic stem (HS) cell recruitment following BMT. In a model of bone development, mouse kidneys engrafted with Cd105 ⁺ /Thy1 ⁻ cells from fetal mice developed bones and bone marrow and successfully recruited HS cells from circulation compared with what was seen in controls. In contrast, grafts of Cd105 ⁺ /Thy1 ⁺ cells developed into bones without marrow and did not recruit HS cells. Next steps include isolating CD105 ⁺ /THY1 ⁻ cells from adult mice and human tissue and using the cells for bone marrow regeneration.	Patent application filed for undisclosed technologies related to this study; licensing information available from Stanford University Contact: Trevor Roubison, Stanford University Office of Technology Licensing e-mail: trevor.roubison@stanford.edu	Chan, K.F.C. <i>et al. Nature</i> ; published online Dec.10, 2008; doi:10.1038/nature07547 Contact: Ching-Cheng Chen, Stanford University, Stanford, Calif. e-mail: c3chen@stanford.edu Contact: Charles K.F. Chan, same affiliation as above e-mail: chazchan@stanford.edu
<i>SciBX</i> 2(3); doi:10.1038/scibx.2009.97 Published online Jan. 22, 2009				